Press releases

"Our third quarter results reflect accelerated growth,” said Mike Mahoney, chairman and CEO, Boston Scientific. Read the October 23, 2019 announcement.

Boston Scientific announced the commencement of a cash tender offer for up to $1.0 billion of outstanding senior notes.

Boston Scientific will webcast its conference call with financial results and business highlights for Q3 ended September 30, 2019.

Study of abbreviated antiplatelet therapy for patients at high risk for bleeding after percutaneous coronary intervention.

Notably, key data from the EVOLVE Short DAPT study of the SYNERGY stent will be featured during a late-breaking science session.

Boston Scientific CEO Mike Mahoney will participate in a conference in September 2019. Learn how to join the webcast or watch the replay.

System is designed to treat Parkinson's Disease symptoms by delivering precisely targeted electrical stimulation.

BTG acquisition brings best-in-class minimally-invasive technologies for procedures targeting cancer and vascular diseases to Boston Scientific.

Physicians will have continued access to the Eluvia™ Drug-Eluting Vascular Stent (DES) System to treat their patients with peripheral artery disease (PAD).

Boston Scientific will participate in an upcoming investor conference in August 2019. A live webcast and replay will be available.

"The consistent execution of our global teams continues to help us grow the majority of our businesses faster than the market,” said Mike Mahoney.

Boston Scientific will webcast its conference call with financial results and business highlights for Q2 ended June 30, 2019. Learn how to tune in.

Momentum across business units and regions targeted to deliver top tier revenue growth and double-digit adjusted earnings per share growth with strong adjusted free cash flow.

Boston Scientific shares the FDA’s dedication to providing the best care possible for the 8.5 million patients in the U.S. with peripheral artery disease (PAD).

Data on the Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System were not included in the meta-analyses that were catalysts for the panel meeting.

Vertiflex acquisition adds the only FDA-approved, commercially available, minimally invasive interspinous spacer to Boston Scientific’s chronic pain portfolio.

WATCHMAN device findings could expand number of non-valvular atrial fibrillation (AFib) patients who can receive alternative treatment to lifelong use of blood thinners.

Boston Scientific (BSX) will participate in an upcoming investor conference in May 2019. A live webcast and replay will be available.

New clinical trial data further support use of Boston Scientific’s EMBLEM S-ICD System as first-line therapy for majority of ICD patients.

Acquisition of lumbar spinal stenosis treatment to expand portfolio of interventional pain therapies.

Boston Scientific will participate in the upcoming healthcare conference in May 2019. A live webcast and replay will be available.

New stent system now available for treating patients with deep venous blockages.

Results includes data about Boston Scientific S-ICD, POLARx cryoablation catheter, WATCHMAN device and LUX-Dx insertable cardiac monitor.

Boston Scientific will participate in the upcoming investor healthcare conference in May 2019. A live webcast and replay will be available.

"With our strong pipeline and category leadership strategy, we are confident in our top tier 2019 outlook,” said CEO Mike Mahoney. Read the April 2019 release.